enGene Holdings changes name to enGene Therapeutics Inc., signals commercial readiness for detalimogene

enGene Therapeutics Inc.

Name change to enGene Therapeutics Inc. effective April 8, 2026; tickers ENGN/ENGNW unchanged.
BLA submission for detalimogene planned for 2H 2026 in BCG-unresponsive NMIBC with CIS.
Potential approval and commercial launch targeted for 2027.
New CUSIP numbers: common shares 29286X101, warrants 29286X119.

item 5.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.